24小时热门版块排行榜

南方科技大学公共卫生及应急管理学院2026级博士研究生招生报考通知（长期有效）

返回列表

当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖

zlwcw

木虫 (著名写手)

应助: 1 (幼儿园)
金币: 2021.1
散金: 225
红花: 8
帖子: 1274
在线: 219.7小时
虫号: 530429
注册: 2008-03-21
性别: GG
专业: 代谢性疾病药物药理

[交流] 50 M 华医获得第一桶金已有6人参与

http://www.msnbc.msn.com/id/4459 ... -commercialization/
上海--(美国商业资讯)--作为中国领先的药物创新研发和发展公司，华医药今天宣布在由ChinaBio® LLC和苏州BioBay共同举办的BioBay 创业投资论坛的协助下，公司获得一批美国和中国著名医疗投资公司5千万美元的融资承诺。这些投资公司有ARCH 风险投资合作公司，富达生命科学，富达亚洲风险投资，Venrock，Sino-Alliance International Ltd和新兴投资公司无锡药明康达风险投资，这些基金将用于推进华医药的内部研发项目以及为其他项目的收购，研发和发展提供资金支持。

中国生物制药 (HK:01177)最新价：2.19 0.04 1.86%行情走势公司新闻大行评级
无锡药明康达财务总监爱德华说，无锡公司风险基金的设立主要是为像华医药这样的公司提供资金支持，这些公司的精英领导者通过各种有效的合作研发创技术和产品，并将它们商业化。华医药所拥有的精英药物研发团队，能够同时开展多个项目，从早期的研发项目，乃至获得项目许可从而使产品顺利在中国进行商业化推广。

华医药董事会成员以及富达亚洲风险投资管理伙伴丹尼尔奥尔·巴赫说："不像大多数新生生物技术公司需要十年或更长的时间才能收益，华医药能够利用其研发，管理和发展的专业资源，从一系列成熟项目中创造可观的短期价值。我们非常高兴华医药能有这样的机遇，公司目前正同多个市政当局探讨在当地为我们的项目建立更多的基础设施。"

华医药首席执行官陈力补充说："华医药致力于建立一种更好的新方法，集合东西方之优势，研发新药并将其商业化，

。我我们有幸能建立一个强大的团队，包括一些著名的医疗投资公司，例如新的公司投资者-作为中国生命科学领域领先企业的无锡药明康达。

华医药的创始人包括陈力博士-罗氏研发中心前首席科学官；杰克鲍德温-默克-Trusopt的发现者以及Pharmacopeia and Vitae PharmaceuticaLS公司的创始人之一和科学主任；约翰蔡-来自Venrock；李革博士-无锡药明康达创始人，总裁和首席执行官；丹尼尔奥尔·巴赫-富达亚洲富达亚洲风险投资管理伙伴；布莱恩罗伯特-来自Venroc以及罗伯特尼尔森-ARCH Venture Partners创始人之一及常务董事。

关于华医药

华医药致力于成为中国一流的、着眼于世界市场的充分整合的生物技术公司。公司充分利用中国低成本但高质量的新药发现能力，并且同亚洲、美国和欧洲的非常有潜力的药物资源进行合作和授权许可交易。通过这些努力，华医药立志成为中国转变为国际药物研发创新中心的驱动力量。

关于BioBay创业投资论坛

第四届年度BioBay创业投资论坛在中国苏州举办。19家早期生命科学企业在会上向50多家投资公司作项目路演。会议由位于上海的咨询和会议主办公司ChinaBio® LLC和中国发展最快的生命科学园苏州工业园区合办。
SHANGHAI, CHINA — Hua Medicine, the leading innovative drug development and commercialization company in China, announced today that it has secured $50 million in new financing commitments from a prestigious group of US and Chinese healthcare investors, including ARCH Venture Partners, Fidelity Biosciences, Fidelity Growth Partners Asia, Venrock, Sino-Alliance International Ltd and new investor WuXi PharmaTech Corporate Venture. These funds are expected to progress Hua's internal development programs as well as provide financial resources for the acquisition, development and commercialization of additional programs.
"WuXi's corporate venture fund was set up to fund companies like Hua Medicine that bring together great minds to develop and commercialize innovative technologies and products through fruitful collaborations," said Edward Hu, Chief Financial Officer of WuXi PharmaTech. "With an elite drug development team, Hua Medicine is well positioned to pursue multiple projects that cover the spectrum from early development programs to in-licensing of assets for successful commercialization in China."
"Unlike most biotechnology start-ups which may take a decade or more to become profitable, Hua is in a position to utilize its development, regulatory and commercialization expertise to create substantial near-term value from a pipeline of late stage programs," said Hua Board Member Daniel Auerbach, Managing Partner of Fidelity Growth Partners Asia. "We are very excited about Hua's opportunities and the company is currently in discussions with a number of municipalities about establishing additional local facilities for our programs."
Hua CEO Li Chen adds, "Hua is focused on building a new and better way to develop and commercialize drugs, leveraging the best of what the Eastern and Western worlds have to offer. We are fortunate to have a strong team that extends to a prominent group of healthcare investors, including new corporate investor, WuXi PharmaTech, the entrepreneurial leader in China's life sciences sector."
Hua was co-founded by Dr. Li Chen, the former Chief Scientific Officer of Roche's R&D Center in China; Jack Baldwin, discoverer of Trusopt at Merck and Co-Founder and CSO of Pharmacopeia and Vitae Pharmaceuticals; John Choi, previously of Venrock; Dr. Ge Li, Founder, Chairman and CEO of WuXi PharmaTech; Daniel Auerbach, Managing Partner of Fidelity Growth Partners Asia; Bryan Roberts of Venrock; and Robert Nelsen, Co-Founder and Managing Director of ARCH Venture Partners.
About Hua Medicine
Hua is focused on becoming the leading, fully-integrated biotech company in China targeting world-wide markets. The company leverages the lower-cost yet highest-quality drug discovery capabilities available in China, while partnering or licensing the most promising drug assets from Asia, the US and EU. Through

[ Last edited by zlwcw on 2011-9-25 at 11:49 ]

回复此楼